Pinnacle Pharmaceuticals, Inc.

Innovative Biologics, Inc.

Noureddine Fahmi

Sidney M Hecht

Frank Schmidtmann

Vladimir Karginov

The invention provides low molecular weight compounds that block the pore formed by protective antigen and inhibit anthrax toxin action. Structures of the compounds are derivatives of &#x3b2;-cyclodextrin. Per-substituted alkylamino derivates displayed inhibitory activity, and they were protective against anthrax lethal toxin action at low micromolar concentrations. Also, the addition of one of the alkylamino derivatives to the bilayer lipid membrane with multiple PA channels caused a significant decrease in membrane conductance. Thus, the invention also provides methods for protection against anthrax toxicity.

&#x3b2;-Cyclodextrin derivatives

The invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance. This new class of antibiotics are derivatives of &#x3b2;-cyclodextrin (&#x3b2;-CD), which is a cyclic molecule comprising seven D-glucose units.

Growing community of inventors

Charlottesville, VA, United States of America

Noureddine Fahmi